After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

Discover why some biotechs fail but survive with cash on hand, and how players like Concentra are trying to unlock trapped ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or ...

In related developments, Wedbush downgraded iTeos stock from Outperform to Neutral but raised the price target from $10 to $12. Piper Sandler also adjusted its price target for iTeos, reducing it from ...

Detailed price information for Iteos Therapeutics Inc (ITOS-Q) from The Globe and Mail including charting and trades.

Investing.com - Leerink Partners has lowered its price target on iTeos Therapeutics (NASDAQ: ITOS) to $10.00 from $12.00 while maintaining a Market Perform rating on the stock.

In related developments, Wedbush downgraded iTeos stock from Outperform to Neutral but raised the price target from $10 to $12. Piper Sandler also adjusted its price target for iTeos, reducing it ...

Immediately following the closing of the offer, iTeos will be acquired by Concentra, and all remaining shares not tendered in the offer, other than shares owned directly or indirectly by iTeos, ...

WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. ("iTeos") (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement ...

Pursuant and subject to the terms of the merger agreement, Concentra will commence a tender offer by August 1, 2025, to acquire all outstanding shares of iTeos common stock for the Offer ...

Immediately following the closing of the offer, iTeos will be acquired by Concentra, and all remaining shares not tendered in the offer, other than shares owned directly or indirectly by iTeos ...